CM
PTGX icon

Crestline Management’s Protagonist Therapeutics PTGX Stock Holding History

Crestline Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,681
Closed -$489K – 497
2024
Q4 		$489K Buy
+12,681
New +$553K 0.02% 544

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crestline Management's PTGX Position: Q1 2025 in Review

Crestline Management sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 12,681 shares — an estimated $489K sold.

Crestline Management first reported a position in PTGX in Q4 2024 and held it in 1 quarter. The position peaked at $489K in Q4 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Crestline Management reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 12,681 Protagonist Therapeutics shares in Q1 2025, an estimated $489K.
  • Crestline Management first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Protagonist Therapeutics position peaked at $489K in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.